We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+37.35%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$131M
AUM Growth
+$34.5M
Cap. Flow
+$10.2M
Cap. Flow %
7.85%
Top 10 Hldgs %
81.55%
Holding
24
New
6
Increased
6
Reduced
8
Closed
3

Top Buys

1
AYTU icon
AYTU BioPharma
AYTU
+$12.7M
2
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
+$8.5M
3
SCYX icon
SCYNEXIS
SCYX
+$4.01M
4
ELDN icon
Eledon Pharmaceuticals
ELDN
+$3.19M
5
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$2.57M

Top Sells

1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$10M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$5.7M
3
GYRE icon
Gyre Therapeutics
GYRE
+$3.33M
4
ATRS
Antares Pharma, Inc.
ATRS
+$3.25M
5
SBBP
Strongbridge Biopharma plc.
SBBP
+$1.39M

Sector Composition

1 Healthcare 97.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LGND icon
1
Ligand Pharmaceuticals
LGND
$6.08B
$32.4M 24.83%
522,738
+7,373
+1% +$420K
AMYT
2
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$20.1M 15.35%
1,416,483
+651,247
+85% +$8.5M
DMAC icon
3
DiaMedica Therapeutics
DMAC
$393M
$9.63M 7.37%
950,000
-196,470
-17% -$1.07M
AYTU icon
4
AYTU BioPharma
AYTU
$23.1M
$8.37M 6.4%
+69,939
New +$12.7M
APEN
5
DELISTED
Apollo Endosurgery, Inc.
APEN
$7.91M 6.05%
2,326,165
+900,730
+63% +$2.37M
CTIC
6
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$6.61M 5.06%
2,054,000
-1,714,597
-45% -$5.7M
ISEE
7
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.53M 4.23%
800,000
-1,562,240
-66% -$10M
XOMA
8
DELISTED
Xoma
XOMA
$5.48M 4.19%
124,130
-26,083
-17% -$786K
GYRE icon
9
Gyre Therapeutics
GYRE
$675M
$5.26M 4.03%
111,260
-76,928
-41% -$3.33M
SCYX icon
10
SCYNEXIS
SCYX
$42.4M
$5.24M 4.01%
+85,625
New +$4.01M
ADMS
11
DELISTED
Adamas Pharmaceuticals
ADMS
$3.5M 2.68%
808,431
+150,964
+23% +$646K
SBBP
12
DELISTED
Strongbridge Biopharma plc.
SBBP
$3.28M 2.51%
1,350,000
-574,956
-30% -$1.39M
GMDA
13
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$3.18M 2.44%
+379,470
New +$2.57M
CHMA
14
DELISTED
Chiasma, Inc. Common Stock
CHMA
$3.14M 2.4%
721,307
+371,307
+106% +$1.55M
NEOS
15
DELISTED
Neos Therapeutics, Inc
NEOS
$3.1M 2.37%
4,962,657
+578,458
+13% +$357K
ELDN icon
16
Eledon Pharmaceuticals
ELDN
$314M
$2.58M 1.97%
+167,333
New +$3.19M
KA
17
DELISTED
Kineta, Inc. Common Stock
KA
$1.85M 1.42%
+15,550
New +$2.36M
AFMD
18
DELISTED
Affimed
AFMD
$1.28M 0.98%
21,934
-13,833
-39% -$651K
VTGN icon
19
VistaGen Therapeutics
VTGN
$9.4M
$970K 0.74%
+16,667
New +$425K
APVO icon
20
Aptevo Therapeutics
APVO
$5.91M
– –
0
– –
CPIX icon
21
Cumberland Pharmaceuticals
CPIX
$102M
$557K 0.43%
188,703
-400,794
-68% -$1.21M
BIOR
22
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
– –
-272
Closed -$614K
ATRS
23
DELISTED
Antares Pharma, Inc.
ATRS
– –
-1,205,501
Closed -$3.25M
IDXG
24
DELISTED
Interpace Biosciences, Inc. Common Stock
IDXG
– –
-284,730
Closed -$880K

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Stonepine Capital Management held 24 positions worth $131M, up 36% from $96.1M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Stonepine Capital Management deployed $10.2M of net new capital in Q4 2020, opening 6 new positions and adding to 6 existing holdings. Its largest new stake was AYTU BioPharma: 69,939 shares worth $8.37M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier.

On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $10M trimmed.

  • Stonepine Capital Management's largest Q4 2020 buy was AYTU BioPharma: 69,939 shares worth $8.37M.
  • Stonepine Capital Management added most to Amryt Pharma plc American Depositary Shares in Q4 2020, an estimated $8.5M increase.
  • Stonepine Capital Management's biggest Q4 2020 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $10M.
  • Stonepine Capital Management fully exited Antares Pharma, Inc. in Q4 2020, selling an estimated $3.25M.
  • Stonepine Capital Management's ten largest holdings make up 82% of its $131M portfolio in Q4 2020.
  • Stonepine Capital Management opened 6 new positions and closed 3 in Q4 2020.
  • Stonepine Capital Management's portfolio value rose 36% quarter-over-quarter to $131M.

Based on Stonepine Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.